Deutsche Bank AG Buys Shares of 31,693 MBX Biosciences, Inc. $MBX

Deutsche Bank AG purchased a new position in shares of MBX Biosciences, Inc. (NASDAQ:MBX) during the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 31,693 shares of the company’s stock, valued at approximately $1,749,000.

A number of other institutional investors and hedge funds have also modified their holdings of MBX. Wellington Management Group LLP increased its stake in MBX Biosciences by 112.8% in the 3rd quarter. Wellington Management Group LLP now owns 4,823,336 shares of the company’s stock valued at $84,408,000 after purchasing an additional 2,556,708 shares in the last quarter. Deep Track Capital LP grew its holdings in MBX Biosciences by 43.9% in the third quarter. Deep Track Capital LP now owns 3,150,000 shares of the company’s stock valued at $55,125,000 after purchasing an additional 961,408 shares during the last quarter. Vanguard Group Inc. grew its holdings in MBX Biosciences by 8.4% in the fourth quarter. Vanguard Group Inc. now owns 1,817,811 shares of the company’s stock valued at $57,334,000 after purchasing an additional 140,449 shares during the last quarter. Franklin Resources Inc. increased its position in shares of MBX Biosciences by 164.2% in the third quarter. Franklin Resources Inc. now owns 1,307,288 shares of the company’s stock valued at $22,878,000 after buying an additional 812,436 shares in the last quarter. Finally, MPM Bioimpact LLC increased its position in shares of MBX Biosciences by 14.3% in the second quarter. MPM Bioimpact LLC now owns 1,294,416 shares of the company’s stock valued at $14,769,000 after buying an additional 161,466 shares in the last quarter.

Wall Street Analyst Weigh In

MBX has been the topic of several recent research reports. Mizuho boosted their price objective on shares of MBX Biosciences from $57.00 to $91.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Citigroup restated an “outperform” rating on shares of MBX Biosciences in a report on Tuesday, May 12th. JPMorgan Chase & Co. initiated coverage on shares of MBX Biosciences in a report on Friday, August 21st. They issued an “overweight” rating and a $88.00 price target on the stock. Wall Street Zen lowered shares of MBX Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Stifel Nicolaus set a $56.00 price objective on shares of MBX Biosciences in a research note on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.00.

MBX Biosciences Stock Performance

Shares of NASDAQ MBX opened at $63.00 on Friday. The firm has a market cap of $3.03 billion, a P/E ratio of -26.14 and a beta of 0.10. MBX Biosciences, Inc. has a 1 year low of $9.63 and a 1 year high of $72.64. The firm’s 50 day moving average price is $61.80 and its 200 day moving average price is $42.99.

MBX Biosciences (NASDAQ:MBX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.10). As a group, equities analysts predict that MBX Biosciences, Inc. will post -3.11 EPS for the current year.

MBX Biosciences Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.